177 related articles for article (PubMed ID: 11948260)
1. Clinical applications of (18)F-FDG in oncology.
Nabi HA; Zubeldia JM
J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
[TBL] [Abstract][Full Text] [Related]
2. [Positron-emission tomography in oncology].
Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
[TBL] [Abstract][Full Text] [Related]
3. Clinical role of positron emission tomography in oncology.
Bomanji JB; Costa DC; Ell PJ
Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
[TBL] [Abstract][Full Text] [Related]
4. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
Delbeke D
J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effective PET scans in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
[TBL] [Abstract][Full Text] [Related]
6. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
[TBL] [Abstract][Full Text] [Related]
7. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
8. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effective PET investigations in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
Czech N; Brenner W; Kampen WU; Henze E
Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
[No Abstract] [Full Text] [Related]
11. Utility of 18F-FDG PET in evaluating cancers of lung.
Acker MR; Burrell SC
J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications of PET in oncology.
Rohren EM; Turkington TG; Coleman RE
Radiology; 2004 May; 231(2):305-32. PubMed ID: 15044750
[TBL] [Abstract][Full Text] [Related]
13. PET imaging in oncology.
Bar-Shalom R; Valdivia AY; Blaufox MD
Semin Nucl Med; 2000 Jul; 30(3):150-85. PubMed ID: 10928381
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
Kostakoglu L; Goldsmith SJ
J Nucl Med; 2003 Feb; 44(2):224-39. PubMed ID: 12571214
[TBL] [Abstract][Full Text] [Related]
15. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
16. PET/CT in oncology: a major technology for cancer care.
Ell PJ
Chang Gung Med J; 2005 May; 28(5):274-83. PubMed ID: 16086542
[TBL] [Abstract][Full Text] [Related]
17. [Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].
Talbot JN; Rain JD; Meignan M; Askienazy S; Grall Y; Bok B; Misset JL
Bull Cancer; 2002 Mar; 89(3):313-21. PubMed ID: 11940470
[TBL] [Abstract][Full Text] [Related]
18. Perineural spread of melanoma demonstrated by F-18 FDG PET With MRI and pathologic correlation.
Lee TJ; Glastonbury CM; Buckley AF; Eisele DW; Hawkins RA
Clin Nucl Med; 2008 Feb; 33(2):106-8. PubMed ID: 18209529
[No Abstract] [Full Text] [Related]
19. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging.
Sarlis NJ; Gourgiotis L; Guthrie LC; Galen B; Skarulis MC; Shawker TH; Patronas NJ; Reynolds JC
Clin Nucl Med; 2003 Mar; 28(3):208-17. PubMed ID: 12592128
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
Reske SN; Kotzerke J
Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
